Picking up post #88: that is the part I would want checked first.
For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Picking up post #88: that is the part I would want checked first.
For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
Coming back to post #90, because the follow-up matters more than the original answer.
Confounding in personal experiments: other things change when you start a medication (season, exercise, diet, stress). Documenting those confounders helps you understand their contribution to the result.
Generalisability: a robust n-of-1 result applies to you. It does not tell you much about whether the effect generalises to others similar to you, much less to people different from you.
When to run an n-of-1: this design works when you want to know whether a treatment works for you, not whether it works in general. For that purpose, it is efficient.
This follows post #92 rather than contradicting it.
Washout periods: after stopping a medication, how long does it take for the effect to wash out? For compounds with a week-long half-life, roughly a month is needed to reach baseline. Using that washout period in a before-after design strengthens the inference.
Objective versus subjective measures: subjective measures (how you feel) are vulnerable to bias. Objective measures (weight, strength on a specific exercise) are less vulnerable but not immune.
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
An ABAB design with a data table and honest limitations
An ABAB design with a data table and honest limitations Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURPASS-4 ( Lancet , 2021). Please read it before…
|
2 | 45k | 5mo | |
|
Pre-registering a personal experiment, seriously
Pre-registering a personal experiment, seriously — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA , 2021) with SUSTAIN 6 ( N Engl J Med , 2016) and finding the…
|
+96 | 119 | 58k | 14mo |
|
Blinding yourself: practical methods and their limits — the long version
Blinding yourself: practical methods and their limits — the long version Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURMOUNT-OSA ( N Engl J Med , 2024)…
|
+7 | 11 | 1.8k | 22h |
|
Coming back to: Why most self-reports here are not experiments, and that is fine
The question in the title: Why most self-reports here are not experiments, and that is fine I will give what I have already checked below so nobody repeats it. Comparing LEADER ( N Engl J Med , 2016) with…
|
+56 | 62 | 11k | 4mo |
|
Why most self-reports here are not experiments, and that is fine
Why most self-reports here are not experiments, and that is fine — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen SURPASS-2 ( N Engl J Med , 2021) cited in…
|
2 | 46k | 11mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Immortal time bias in a claims-database study — one year on
Posting this under the heading it deserves: Immortal time bias in a claims-database study — one year on Everything below is what sits behind that. Comparing SURPASS-2 ( N Engl J Med , 2021) with SURMOUNT-1 (…
|
+41 | 46 | 3.7k | 22h |
|
Washout: how long is long enough, and for what purpose
Washout: how long is long enough, and for what purpose — setting out what I have, and where I think it stops being reliable. A documentation question rather than an analytical one. I have a certificate in…
|
+63 | 70 | 13k | 10mo |
|
Revisiting: Semaglutide formulation: what is in the licensed product besides the peptide
Posting this under the heading it deserves: Revisiting: Semaglutide formulation: what is in the licensed product besides the peptide Everything below is what sits behind that. I have seen SURMOUNT-4 ( JAMA ,…
|
+72 | 77 | 7.2k | 19mo |
|
Trifluoroacetate content and its consequences
Trifluoroacetate content and its consequences — setting out what I have, and where I think it stops being reliable. A documentation question rather than an analytical one. I have a certificate in front of me…
|
+123 | 134 | 31k | 5mo |
|
The decimal-point error, and the habit that catches it
The decimal-point error, and the habit that catches it Writing it up because I had to work it out twice and would rather nobody else did. Practical question with the units stated, because I have seen how…
|
+110 | 121 | 10k | 7mo |